Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Korea's New DRG System Sparks Threats Against Health Ministry

This article was originally published in PharmAsia News

Executive Summary

Police are investigating threats triggered by the ministry’s plan to launch a mandatory diagnosis-related group system in July despite opposition from doctors.

You may also be interested in...



China's Pilot DRG Reimbursement Systems Indicate Substantial Changes To Hospital Prescription Habits

SHANGHAI - China is experimenting with pilot reimbursement programs that rely on diagnosis related groups (DRG) in cities across the country, looking for ways to reduce medical expenses

OECD Recommends Changes in Korea's Healthcare System In Its First Survey Of Korea's Pharma Sector

SEOUL - OECD has recommended a set of changes - some of them already pursued by the South Korean government - to get South Korea's healthcare system working more efficiently to curtail rapid increases in healthcare spending

Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III

Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC081450

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel